Causes of Multiple Sclerosis Explained

MS is classified as an immune-mediated disease, but its exact trigger isn’t fully understood. Current research points to a combination of factors:

• Autoimmune dysfunction: The immune system mistakenly targets myelin and the oligodendrocyte cells that produce it, causing demyelination and disrupted nerve signaling.
• Genetic susceptibility: Certain gene variants (notably in the HLA region) increase MS risk, though MS is not directly inherited in a simple pattern.
• Environmental triggers: Low vitamin D levels, smoking, obesity in adolescence, and prior Epstein-Barr virus (EBV) infection are the most consistently linked environmental risk factors.
• Geographic and demographic patterns: MS is more common at higher latitudes and affects women roughly 2–3 times more often than men, though the reasons for this remain under investigation.
• Inflammatory lesion activity: Recurrent immune attacks create focal lesions in the brain and spinal cord visible on MRI, which correlate with relapses and, over time, with disability accumulation.
• Neurodegeneration over time: Independent of relapses, progressive axonal loss and reduced remyelination capacity contribute to long-term disability, particularly in progressive MS subtypes.

Because MS subtype (relapsing-remitting, secondary progressive, primary progressive) significantly affects which treatments — including cell-based ones — are appropriate, subtype classification is one of the first steps in any evaluation at Viezec. See Diagnosis for how this is determined, or our general mechanism explainer for how regenerative approaches interact with these disease processes.

Symptoms of Multiple Sclerosis

MS symptoms vary widely depending on which nerve pathways are affected and often occur in relapses (acute episodes) or progress gradually over time. Common symptoms include:

• Numbness or weakness, typically in one limb or one side of the body, often the first noticeable sign.
• Vision problems, including blurred or double vision, or optic neuritis (pain with eye movement and vision loss in one eye).
• Lhermitte’s sign — a brief electric-shock sensation running down the spine or limbs, triggered by neck flexion.
• Balance and coordination difficulty, including unsteady gait or tremor.
• Fatigue — one of the most common and disabling MS symptoms, often disproportionate to physical activity.
• Bladder, bowel, or cognitive changes, including urgency, constipation, or difficulty with memory and processing speed.

⚠️ When to seek urgent evaluation: Sudden vision loss, rapidly worsening weakness, or new severe balance problems warrant prompt neurological assessment — early diagnosis and treatment initiation are linked to better long-term outcomes in MS.

Diagnosis of Multiple Sclerosis

There is no single test for MS — diagnosis relies on the McDonald criteria, which combine clinical history, imaging, and lab findings to demonstrate disease activity that is disseminated in both time and space (i.e., lesions occurring at different times and in different parts of the CNS). At Viezec, our neurology partners use:

Why subtype matters for treatment eligibility: Relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) respond differently to both DMTs and cell-based approaches. AHSCT trial data, for instance, applies specifically to active relapsing-remitting disease — not to primary progressive MS. This is confirmed through your MRI and clinical history before any protocol, including MSC or AHSCT-based options, is discussed.

Send your MRI and clinical reports for a free specialist review rather than repeating recent imaging unnecessarily.

Stem Cell Treatment for Multiple Sclerosis

Two distinct approaches — know the difference before reading further

Mesenchymal stem cell (MSC) therapy uses cells (from bone marrow, adipose tissue, or umbilical cord) delivered via IV infusion or intrathecal injection, aiming to modulate immune activity and support the CNS repair environment. This remains an investigational approach studied mainly in phase I/II trials.

Autologous hematopoietic stem cell transplant (AHSCT) is a different, more intensive procedure: a patient’s own blood-forming stem cells are harvested, the patient then undergoes immune-ablative chemotherapy, and the harvested cells are re-infused to rebuild (“reboot”) the immune system. This is not a simple infusion — it involves a hospital admission, conditioning chemotherapy, and a recovery period, similar in intensity to a bone marrow transplant for blood cancers. AHSCT has completed phase II and phase III randomized trial data, including the MIST trial (Burt et al.), which found AHSCT significantly reduced disease progression compared to continued standard disease-modifying therapy in patients with highly active relapsing-remitting MS.

How each works

• MSC mechanism: Cells migrate toward inflamed tissue, release anti-inflammatory and neuroprotective signaling factors, and are studied for their potential to support an environment favorable to remyelination — without directly replacing damaged nerve cells.
• AHSCT mechanism: Immune-ablative conditioning eliminates the autoreactive immune cells thought to drive MS relapses; reinfused stem cells then regenerate a new immune system that, in successful cases, no longer attacks myelin in the same way.

Procedure at Viezec

1. Neurological evaluation — MRI review, relapse history, EDSS scoring, and MS subtype confirmation.
2. Pathway discussion — based on your evaluation, our specialist team discusses whether MSC-based therapy, AHSCT (via partner transplant centers), neither, or continued standard DMT is the most appropriate next step. Not every patient is a candidate for either cell-based option.
3. Cell sourcing and GMP processing — autologous or allogeneic MSC preparation under GMP-compliant lab conditions, or coordination with an accredited transplant center for AHSCT.
4. Administration — IV infusion or intrathecal delivery for MSC-based protocols (see Delivery Methods); inpatient conditioning and transplant procedure for AHSCT.
5. Follow-up — neurology-led monitoring, physiotherapy, and rehabilitation therapy over 3–12 months.

Expected outcomes

MSC-based protocols are studied for potential reductions in relapse frequency and improved fatigue/mobility measures over 3–12 months, with variable results. AHSCT, in trial and real-world cohort data, has shown higher rates of sustained disease stabilization in appropriately selected relapsing-remitting patients — see Success Rates for specific figures and their sources.

Disclaimer: Neither approach is guaranteed to work for every patient, and both carry procedural risks that your specialist will review individually — see Treatment Disclaimer.

Stem Cell Delivery Methods — Multiple Sclerosis

Delivery route depends entirely on which approach applies to your case:

For MSC-based protocols:

• Intravenous (IV) infusion — used when broader, systemic immunomodulatory effects are the goal; the most common route for MSC therapy in MS.
• Intrathecal administration — delivers cells directly into the cerebrospinal fluid for more direct CNS exposure; used selectively based on disease pattern and specialist judgment.

For AHSCT:

• Cells are harvested via peripheral blood stem cell collection (after mobilization with medication), cryopreserved, and later re-infused intravenously following conditioning chemotherapy — a substantially different procedure from a single MSC infusion, requiring inpatient hospital care.

All procedures at Viezec-affiliated facilities follow GMP-compliant cell processing and strict aseptic protocols, with neurological monitoring before and after delivery. For general background on how delivery route is chosen across conditions, see our Stem Cell Delivery Methods overview page.

Improvements & Results

Reported improvements differ by approach and should be read that way rather than as one pooled outcome:

For MSC-based protocols

• Reduced fatigue and improved energy for daily activity
• Improved balance, coordination, and gait stability
• Reduced spasticity and muscle stiffness
• Improved bladder/bowel control in some patients

For AHSCT (trial and cohort data)

• Reduced relapse rate — often the primary outcome tracked
• Stabilization or improvement in EDSS (disability) scores over 1–5 years of follow-up
• Reduction in new MRI lesion activity

Patient-reported experience (unverified quotes — see note under Testimonial)

“My walking is steadier after physiotherapy and energy management; I can attend social events more often.” — Patient from Bengaluru, India

“Spasticity treatments and advice helped reduce pain and made daily tasks easier to manage.” — Caregiver from Toronto, Canada

Consult Our Specialists

Mechanism of Action: MSC vs. AHSCT in Multiple Sclerosis

MSC mechanism:

• Immune modulation — MSCs help rebalance abnormal immune responses that drive attacks on myelin.
• Neuroprotection — MSCs release growth factors and antioxidants that may help protect nerve cells from ongoing damage.
• Remyelination support — research suggests MSCs may create a microenvironment more favorable to natural repair processes, without directly generating new myelin themselves.
• Inflammation control — reduction of chronic neuroinflammation associated with MS relapses.

AHSCT mechanism:

• Immune ablation — high-dose chemotherapy eliminates the existing, autoreactive immune cell population thought to drive MS activity.
• Immune system reconstitution — reinfused hematopoietic stem cells rebuild a new immune system, which in successful cases develops without the same autoreactive pattern against myelin.
• This is a fundamentally different mechanism from MSC infusion — it doesn’t add reparative cells to existing tissue, it replaces the immune system that’s causing the damage.

At Viezec, this distinction directly shapes which specialists and partner facilities are involved in your care, and is explained in full during your evaluation. See also our general mechanism overview and safety and adverse effects pages for how these mechanisms translate to real-world risk profiles.

Our Promise

At Viezec, our approach to Multiple Sclerosis care is built on being clear about what each option can and cannot currently deliver:

• No cure claims, for either approach. MSC therapy and AHSCT are both discussed as tools to manage disease activity — never marketed as a cure for MS.
• Full disclosure of the MSC/AHSCT distinction. We explain which approach is being discussed, why, and what evidence level applies to it, before any decision is made.
• Diagnosis and subtype confirmation before any pathway discussion — see Diagnosis.
• Named, credentialed medical oversight. (Add your treating neurologist/specialist’s name and credentials here directly — this is the single highest-trust addition for this page, particularly given AHSCT involves referral to a transplant-capable facility.)
• Regulatory transparency. MSC-based interventions in India operate within ICMR guidelines for investigational use; AHSCT, where recommended, is coordinated through accredited transplant centers following established hematology-oncology protocols.
• Accredited facilities — NABH accreditation (Reg. No. ___) and NABL accreditation (Reg. No. ___). (Insert actual numbers — same recommendation as on the infertility page.)
• Written, itemized cost estimates after evaluation, reflecting which specific pathway applies to your case.
• Location and access clarity — our coordinating facility is based at H-23/B, Top Floor, Abul Fazal Enclave Part 1, New Delhi – 110025, India, with dedicated international patient support.

Treatment Results

Patients receiving MSC-based therapy at Viezec-affiliated facilities have reported reduced relapse frequency, improved balance, decreased spasticity, and better stamina for daily activities — though the extent of benefit varies significantly by MS subtype, baseline disability, and immune status. AHSCT, coordinated through accredited transplant partner facilities, has shown in trial and cohort data a stronger and more durable ability to stabilize disease activity in appropriately selected relapsing-remitting patients — see Success Rates below for specific figures with sources.

Regular monitoring — neurological exams, MRI imaging, and EDSS scoring — is used to evaluate response for both approaches. Neither is a guaranteed cure, and outcomes differ meaningfully between patients; this is explained further in our Treatment Disclaimer.

Discuss Your Case

Testimonials

Neha S. – Delhi, India – February 2020 – ⭐⭐⭐⭐☆
“MS flare-ups had left me exhausted and weak. After Viezec’s stem cell therapy, my energy improved and relapses became less frequent.”

James W. – Boston, USA – September 2020 – ⭐⭐⭐⭐⭐
“I had constant numbness in my legs. Post-treatment at Viezec, sensation started returning, and I can now walk longer without fatigue.”

Aisha K. – Riyadh, Saudi Arabia – January 2021 – ⭐⭐⭐⭐☆
“My MS symptoms worsened every year. After Viezec’s therapy, my balance improved, and I feel more confident moving around.”

Emma P. – London, UK – July 2021 – ⭐⭐⭐⭐⭐
“Viezec’s doctors were supportive throughout. Stem cell therapy reduced my tremors, and I can write and type with better control again.”

Carlos H. – Madrid, Spain – March 2022 – ⭐⭐⭐⭐☆
“Walking was a challenge with MS. After stem cell therapy, my mobility improved and I depend less on walking aids.”

Amira N. – Cairo, Egypt – October 2022 – ⭐⭐⭐⭐⭐
“Stem cell therapy at Viezec helped stabilize my condition. My vision became clearer, and fatigue has reduced significantly.”

Daniel R. – Toronto, Canada – April 2023 – ⭐⭐⭐⭐☆
“I used to struggle with constant muscle weakness. Post-treatment, my strength improved, and daily activities feel less tiring.”

Sofia G. – Rome, Italy – September 2023 – ⭐⭐⭐⭐⭐
“Viezec’s therapy helped me regain balance and reduced spasms. I feel more independent and hopeful about my future.”

Oliver M. – Sydney, Australia – January 2024 – ⭐⭐⭐⭐☆
“My coordination issues improved after therapy. With Viezec’s care, I feel steadier on my feet and less worried about relapses.”

Fatima H. – Dubai, UAE – June 2025 – ⭐⭐⭐⭐⭐
“Stem cell therapy gave me back control over my life. My MS symptoms have reduced, and I enjoy a much better quality of life now.”

Treatment Disclaimer

Is stem cell therapy a cure for Multiple Sclerosis?

No — neither MSC-based therapy nor AHSCT is a cure. Both aim to manage disease activity (relapses, inflammation, disability progression), not reverse MS or guarantee remission. Ahead of any procedure, patients should understand this is an evolving field, and in some cases a patient may be found ineligible for a specific pathway, or the proposed protocol may change, based on medical evaluation.

What does current evidence show?

AHSCT has completed phase II and phase III randomized trial data (including the MIST trial) specifically for highly active relapsing-remitting MS. MSC-based therapy for MS is supported by smaller phase I/II trials and observational studies; larger controlled trials are still needed to establish it as standard practice. Neither approach is currently recognized as a standard first-line MS treatment by major bodies such as the American Academy of Neurology or ECTRIMS — both remain either investigational (MSC) or a specialist-referral option for a defined patient subgroup (AHSCT).

Who oversees treatment decisions?

All pathway decisions are made following full neurological evaluation, MRI review, and disease history, overseen by named specialists — AHSCT specifically requires coordination with an accredited transplant-capable facility, not a standalone infusion clinic.

What results can I realistically expect?

Results vary significantly by MS subtype, disease duration, prior treatment response, and baseline disability. We do not publish blanket success percentages because outcomes differ meaningfully between patients — your specialist will discuss what’s realistic for your specific case.

Where can I get a specific answer for my case?

Book a consultation with our specialist team to review your MRI, relapse history, and current treatment, and discuss which pathway — if any — is appropriate.

As with any medical treatment, no guarantees or claims of cure are made. We do not use embryonic or fetal cells in any of our protocols.